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Abstract
In open trials, 1-Hz repetitive transcranial magnetic stimulation (rTMS) to the supplementary motor area
(SMA) improved symptoms and normalized cortical hyper-excitability of patients with obsessive–
compulsive disorder (OCD). Here we present the results of a randomized sham-controlled double-blind
study. Medication-resistant OCD patients (n=21) were assigned 4 wk either active or sham rTMS to the
SMA bilaterally. rTMS parameters consisted of 1200 pulses/d, at 1 Hz and 100% of motor threshold (MT).
Eighteen patients completed the study. Response to treatment was defined as a o25% decrease on the
Yale–Brown Obsessive Compulsive Scale (YBOCS). Non-responders to sham and responders to active or
sham rTMS were offered four additional weeks of open active rTMS. After 4 wk, the response rate in the
completer sample was 67% (6/9) with active and 22% (2/9) with sham rTMS. At 4 wk, patients receiving
active rTMS showed on average a 25% reduction in the YBOCS compared to a 12% reduction in those
receiving sham. In those who received 8-wk active rTMS, OCD symptoms improved from 28.2¡5.8
to 14.5¡3.6. In patients randomized to active rTMS, MT measures on the right hemisphere increased
significantly over time. At the end of 4-wk rTMS the abnormal hemispheric laterality found in the group
randomized to active rTMS normalized. The results of the first randomized sham-controlled trial of SMA
stimulation in the treatment of resistant OCD support further investigation into the potential therapeutic
applications of rTMS in this disabling condition.
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Introduction
Up to 40–60% of obsessive–compulsive disorder
(OCD) patients do not have a satisfactory outcome
with currently available treatments (Pallanti et al.
2002 ; Simpson et al. 2006). The goal of the present
study was to evaluate non-invasive focal repetitive
transcranial magnetic stimulation (rTMS) for treat-
ment-resistant OCD.
Some neurobiological models have associated OCD
pathophysiology to deficits in inhibition of irrelevant
information and response control (Chamberlain et al.
2005 ; van den Heuvel et al. 2005). Such models would
explain the reduced ability of OCD patients to inhibit
intrusive thoughts, impulses, or images and repetitive
motor responses and have been associated with ex-
cessive activity in orbitofronto-striatal regions, but
also in medial and lateral frontal areas [e.g. sup-
plementary motor area (SMA), anterior cingulate,
dorsolateral prefrontal cortex], and in parietal regions
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(Menzies et al. 2008). We found enhanced precentral
somatosensory evoked potentials and hypofunction-
ing of centrifugal sensory gating in OCD that might
reflect the inability to modulate sensory information
due to a tonic high level of cortical excitability of
motor and related areas (Rossi et al. 2005). Using TMS
as a probe of cortical excitability, Greenberg et al.
(1998, 2000) found that OCD patients had markedly
decreased intracortical inhibition in primary motor
cortex.
Consistent with these physiological findings, a
recent neuroimaging study suggested that premotor
areas, such as SMA and dorsal anterior cingulate
(dAC), are hyperactive in OCD, and that this hyper-
activity may relate to deficient inhibitory control
(Yu¨cel et al. 2007). The increased activation of SMA
and dAC was interpreted to be compensatory, but it is
possible that hyperactivation in these brain regions
could represent a primary aspect of OCD. Whether
hyperactivation in premotor regions is primary or com-
pensatory is difficult to resolve by functional neuro-
imaging or neurophysiological studies alone. Focally
altering cortical excitability via rTMS represents a
means of testing the functional role of these findings.
A handful of studies examined the impact of rTMS
on OCD with variable results. Greenberg et al. (1997)
found that a single session of high-frequency rTMS to
the right lateral prefrontal cortex significantly de-
creased compulsive urges. A double-blind study using
right prefrontal low-frequency rTMS and a less focal
coil failed to find significant effects (Alonso et al. 2001).
In contrast, an open study in refractory OCD patients
assigned to right or left dorsolateral prefrontal cortex
(DLPFC) with high-frequency rTMS found clinically
significant and sustained improvement in a third of
patients (Sachdev et al. 2001). Recently Prasko et al.
(2006) and Sachdev et al. (2007) found that either low-
or high-frequency rTMS administered over the left
DLPFC did not differ from sham (placebo).
Given the evidence for deficient inhibition in OCD,
the use of low-frequency rTMS, which has been re-
ported to be inhibitory on motor cortex excitability
(Chen et al. 1997), may be a fruitful avenue to explore
as a putative treatment. Furthermore, given the evi-
dence of hyperactivation in SMA, a region that plays a
central role in the higher cortical control of motor
subroutines and the organization of motor actions in
sequential order, low-frequency rTMS to SMA may be
worth examining. If low-frequency rTMS to SMA im-
proves symptoms and dampens hyperexcitability, that
would be consistent with the model that functional
hyperactivation seen in that region is primary rather
than compensatory.
To test the potential value of low-frequency rTMS
to SMA, we performed an open-label study on 10
patients with treatment-resistant OCD and Tourette’s
syndrome (TS) (Mantovani et al. 2006). OCD symp-
toms improved by an average of 29%, and improve-
ments were significantly correlated with increases in
right hemisphere motor threshold (MT) and normal-
ization of baseline hemispheric asymmetry of cortical
excitability. Sustained benefit was seen at 3-month
follow-up. Subsequently we reported clinical benefit
ino2 cases of comorbid OCD and TS (Mantovani et al.
2007). While these open-label data are encouraging,
it is important to determine whether improvements
would be evident in a sham-controlled design.
Here we present a randomized sham-controlled
trial of low-frequency rTMS to SMA in treatment-
resistant OCD, and test the hypothesis that inhibiting
this system, as evidenced by MT change, will be
associated with clinical improvement.
Method
Design
This trial consisted of two phases : (1) 4-wk double-
blind, and (2) 4-wk open-label. In phase 1 patients
were randomly assigned in a 1 :1 ratio to either active
rTMS or sham, 5 times/wk, for 4 consecutive weeks.
At the end of 4 wk, non-responders to sham and re-
sponders (as defined below) to either active or sham
rTMS were offered the option of receiving open-label
rTMS for an additional 4 wk in phase 2. Responders
were invited back at 3 months following the last rTMS
to assess persistence of benefits during naturalistic
follow-up.
Subjects
All patients gave written informed consent, and
the protocol was approved by the New York State
Psychiatric Institute/Columbia University IRB. To be
eligible patients had to be aged between 18 yr and
70 yr, have a primary diagnosis of OCD (confirmed by
Structured Clinical Interview for DSM-IV; First et al.
1997), current episode duration of at least a year, have
residual OCD symptoms [defined as a total Yale-
Brown Obsessive Compulsive Scale (YBOCS) score of
o16] (Goodman et al. 1989a, b) despite treatment with
an adequate trial of a serotonin re-uptake inhibitor
(SRI) and cognitive behaviour therapy (CBT). An
adequte SRI trial was defined as treatment for at least
12 wk on the SRI, that meets or exceeds recommended
dosage level for OCD (Koran et al. 2007). Individuals
who could not tolerate, due to side-effects, medications
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of this class at the specified dose and duration were
also included. An adequate trial of CBT was defined as
at least once a week for 8 wk with clear evidence
of exposure during sessions and homework given.
Patients currently on medication and/or psycho-
therapy must have been in stable treatment for at
least 12 wk before initiation and throughout the
study. Patients were excluded if they were treatment-
refractory [defined as non-response to clomipramine,
at least two selective SRIs (SSRIs) at adequate dose and
duration plus CBT in the last year], diagnosed with
severe major depressive disorder (MDD) [defined as
Clinical Global Impression (CGI) o4], exhibited sig-
nificant acute suicide risk, or had a history of bipolar
disorder, of any psychotic disorder, or of substance
abuse or dependence within the past year. Patients
with neurological disorders, increased risk of seizure,
use of proconvulsant medications (such as, bupropion,
maprotiline, tricyclic antidepressants, classical anti-
psychotics), implanted devices, metal in the brain,
unstable medical conditions, pregnancy, or breast-
feeding were excluded. To avoid confounds on motor
cortex excitability measures, medications with a
known inhibitory effect on brain excitability (e.g. anti-
convulsants, benzodiazepines, atypical antipsychotics)
were not allowed. We excluded patients with prior
TMS exposure to reduce risk of unblinding.
Twenty-one outpatients (eight female ; mean age=
38.9 yr, S.D.=11.9) who met study criteria were re-
cruited between January 2005 and December 2007
from the Brain Behavior Clinic and the Anxiety Dis-
orders Clinic of New York State Psychiatric Institute/
Columbia University. Of these, three did not complete
the study for the reasons described below. Analyses
were conducted on the entire sample and on the 18
completers (nine in the active and nine in the sham
group).
Fourteen patients had as their primary symptoms
aggressive and somatic obsessions and checking com-
pulsions, two had contamination obsessions and
cleaning compulsions, two had symmetry obsessions
and counting, repeating, ordering compulsions. Five
patients were on fluoxetine (average dose 76 mg/d),
two on S-citalopram (average dose 30 mg/d), two on
citalopram (average dose 60 mg/d), two on fluvox-
amine (average dose 300 mg/d), and two on sertraline
(average dose 225 mg/d). Five patients were on talk
therapy during the trial. Ten patients met criteria for
moderate non-psychotic MDD.
Outcome measures and response criteria
Patients were evaluated every 2 wk by raters blind to
treatment assignment and also completed self-rating
forms at the end of each week of treatment. Clinical
measures included: YBOCS and YBOCS – Self-rating
(YBOCS-SR), Hamilton Depression Rating Scale – 24-
item (HAMD-24), Hamilton Anxiety Rating Scale – 14
item (HAMA-14), Beck Depression Inventory – II
(BDI-II), Zung Self-Administered Scale (Zung-SAS),
CGI – Severity (CGI-S), Patient Global Impression
(PGI). The primary efficacy measure was the YBOCS.
Patients with a 25% YBOCS reduction at the end of
phase 1 were classified as responders (Simpson et al.
2008).
Side-effect ratings
Before and after each session patients were asked a
series of questions in a structured form in order to rate
TMS side-effects.
rTMS methods
rTMSwas administered with the Magstim super-rapid
stimulator (Magstim Company Ltd, UK) using a vac-
uum cooled 70-mm figure-of-eight coil. Stimulation
parameters were 1-Hz, 20-min train (1200 pulses/d) at
100% of resting MT (using the lowest value of right or
left hemisphere), once a day, 5 d/wk, for 4 wk (in
phase 1) to 8 wk (in phase 2). The coil was positioned
over pre-SMA, targeted using the International 10–20
EEG System (Choi et al. 2006). Pre-SMAwas defined at
15% of the distance between inion and nasion anterior
to Cz (vertex) on the sagittal midline. The coil was
placed with the handle along the sagittal midline,
pointing towards the occiput to stimulate bilaterally
and simultaneously the pre-SMA.
MT
Resting MT was defined as the minimum magnetic
flux needed to elicit a threshold EMG response (50 mV
in peak-to-peak amplitude) in a resting target muscle
(abductor pollicis brevis) in 5/10 trials using single-
pulse TMS administered to the contralateral primary
motor.
Blinding
Sham rTMS was administered using the Magstim
sham coil which contains a mu-metal shield that di-
verts the majority of the magnetic flux such that a
minimal (<3%) magnetic field is delivered to the
cortex (Rossi et al. 2007). This coil looks and sounds
like an active coil ; however, it does not feel like
active rTMS, which generates a tapping sensation on
the scalp. In order to maintain the blind, we kept the
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raters blinded to treatment condition and created a
separation between clinical team and rTMS treating
physician. We also excluded patients who received
TMS before.
Statistical analysis
Besides classifying patients according to categories of
response, statistical analyses were performed using
SPSS library, version 13.0 (SPSS Inc., USA). A worst-
case scenario analysis was computed on the entire
sample. x2 and Student’s t tests were applied to com-
pare demographic, clinical and neurophysiological
data between the active and sham groups. x2 was used
in the completer sample to compare response rate be-
tween the two groups ; Fisher’s exact test was used
when expected counts in a cell were <5. Repeated-
measures analysis of variance (ANOVA), with adjust-
ments for non-sphericity, were applied to evaluate
group and time-dependent effects of rTMS on
psychometric scale mean scores. We used the same
statistical approach to test whether rTMS affects
measures of motor cortex excitability. Student’s t test
was applied to analyse differences in rating scales
mean scores between baseline and 3-month follow-up.
Pearson’s correlations were applied to examine the
relationship between changes in scores of depression
and anxiety measures, and change in OCD scores and
similarly change in clinical global impressions, and
change in OCD scores. Baseline HAMD-24 was used
as covariate in the ANOVA (ANCOVA) to examine
the effect of depression on OCD symptom changes.
Correlations were also performed to test whether
baseline motor cortex excitability measures were re-
lated to response. All tests were conducted with two-




Of the 123 patients screened, 78 were eligible for the
study, but only 21 were randomized and assigned to
either active or sham rTMS. Most patients were ex-
cluded (n=45) because of comorbid severe MDD
(n=21), comorbid bipolar disorder (n=4), presence of
psychosis (n=2), comorbid TS (n=1), history of seiz-
ures (n=4), currently on non-allowed medications
(n=11), never tried conventional treatments for OCD
(n=2). Fifty-seven eligible patients declined partici-
pation before randomization. The main reasons for de-
clining participation were unwillingness to participate
in research (n=17), lack of time (n=12), unable to
commute long distances every day (n=28).
Demographics and baseline clinical characteristics of
the study population
As shown in Table 1, the active and sham groups did
not differ significantly in demographics or baseline
clinical ratings.
Randomized phase (phase 1)
Twenty-one patients entered and 18 completed phase
1. The three, who did not complete the study, were
withdrawn before starting rTMS (two experienced a
worsening of depression and the other fainted during
MT determination). Applying a worst-case scenario
analysis and assuming that of those three non-com-
pleters the two randomized to active were classified as
non-responders and the one randomized to sham as a
responder, at 2 wk the response rate of the entire
sample was 36% (4/11) with active and 10% (1/10)
with sham rTMS. At 4 wk, response rate in the entire
sample was 54% (6/11) with active and 20% (2/10)
with sham rTMS. Analysis of 18 completers showed at
2 wk a response rate of 44% (4/9) with active and 11%
(1/9) with sham rTMS (Fisher’s exact test, p=0.294).
At 4 wk, response rate in the same 18 completers was
67% (6/9) with active and 22% (2/9) with sham rTMS
(Fisher’s exact test, p=0.153).
Clinical measures at baseline, after 2 wk, and 4 wk
active or sham rTMS are presented in Table 2.
Repeated-measures ANOVA revealed a significant
main effect of time on OCD (YBOCS, YBOCS-SR),
anxiety (HAMA-14, Zung-SAS), global assessment
(CGI-S, PGI), and depression (BDI-II). The only
measure that did not show a significant main effect
of time was the HAMD-24.
Timergroup interactions were examined to deter-
mine which of these improvements with time were
related to active vs. sham group assignment. The only
significant timergroup interactions were seen with
YBOCS-SR and CGI-S (Table 2). Timergroup inter-
action on the YBOCS-SR remained significant after
controlling for baseline HAMD-24 (F=2.6, d.f.=4,
p=0.043). On average, the active group showed a 25%
reduction in YBOCS at 4 wk, while the sham group
showed a 12% reduction. On the YBOCS-SR the active
group showed a 30% reduction at 4 wk, while the
sham group showed an 8% reduction.
Changes in depression and anxiety were not corre-
lated with YBOCS and CGI-S changes from baseline.
Correlations were significant between OCD symptoms
and clinical global improvements in both self- and
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clinician-rated scales (R=0.6, p=0.004 and R=0.7,
p=0.001, respectively).
Open-label phase (phase 2)
Of 15 patients eligible to continue, 12 entered and
completed the open-label phase (four initially ran-
domized to active and eight to sham). The other three
(two responders to active and one to sham) decided
not to receive an additional 4-wk active rTMS.
Demographics, symptoms ratings, and MT of those
entering the open-label phase did not differ signifi-
cantly from those who did not enter this phase.
The four patients initially randomized to active
who received an additional 4-wk active rTMS showed
further improvements from week 4 to week 8 on
YBOCS (from 17.7¡2.6 to 14.5¡3.6) and YBOCS-SR
(from 17.2¡2.2 to 14.7¡2.9 ; F=10.7, d.f.=2,
p=0.010). The eight initially randomized to sham had
no significant change in their OCD symptoms after
4-wk active rTMS (YBOCS mean scores slightly in-
creased, from 25.6¡7 to 26.3¡8.5, while YBOCS-SR
mean scores decreased from 27¡7.3 to 25.3¡8.2).
Since the open-label phase represents a mixture of
patients who received active or sham in phase 1, we
conducted separate analyses on those initially rando-
mized to active (termed ‘continued-active rTMS’) and
those initially randomized to sham (termed ‘sham-to-
active rTMS’).
Repeated-measures ANOVA revealed that the con-
tinued-active group, which received 8-wk active
rTMS, had a significant main effect of time on YBOCS
(F=13.2, d.f.=4, p=0.000), YBOCS-SR (F=7.3, d.f.=8,
p=0.000), BDI-II (F=8.3, d.f.=4, p=0.002), HAMA-14
(F=3.7, d.f.=4, p=0.035), Zung-SAS (F=3.8, d.f.=4,
p=0.030), CGI-S (F=10.7, d.f.=4, p=0.001), and PGI
Table 1. Demographic and clinical characteristics of the completers
Active rTMS Sham p
Sample size 9 9 –
Right-handed 8 8 n.s.
Female/Male 4/5 3/6 n.s.
Age (mean¡ S.D.) 39.7¡8.6 yr 39.4¡10.2 yr n.s.
Employed/unemployed 7/2 6/3 n.s.
Age of onset 16.7¡8.3 yr 16.8¡10.1 yr n.s.
Duration of illness 22.4¡13.8 yr 22.1¡7.3 yr n.s.
Duration of current episode 3.5¡3.7 yr 5.3¡5.5 yr n.s.
No. of SRI trials in the current episode 2.7¡1.2 2.7¡1.7 n.s.
No. of patients with co-morbid MDD 4 6 n.s.
No. of patients on SRI 6a 6b n.s.
No. of patients on psychotherapy 3 2 n.s.
Baseline YBOCS 26¡5.4 26.7¡5.5 n.s.
Baseline YBOCS-SR 26.1¡5.7 27.3¡6.9 n.s.
Baseline HAMD-24 15.3¡10.6 14.8¡7.7 n.s.
Baseline BDI-II 21.2¡15.4 15.4¡10.2 n.s.
Baseline HAMA 17.4¡10 14.2¡7.1 n.s.
Baseline Zung-SAS 39.3¡10 35.6¡8.3 n.s.
Baseline CGI-S 5¡0.7 5.2¡0.9 n.s.
Baseline PGI 4.2¡0.9 5.2¡0.8 n.s.
rTMS, Repetitive transcranial magnetic stimulation; SRI, serotonin reuptake
inhibitor ; MDD, Major depressive disorder ; YBOCS, Yale–Brown Obsessive
Compulsive Scale ; YBOCS-SR, YBOCS-Self-rating ; HAMD-24, Hamilton Depression
Rating Scale – 24-item; BDI-II, Beck Depression Inventory – II ; HAMA-14, Hamilton
Anxiety Rating Scale – 14-item; Zung-SAS, Zung Self- Administered Scale ; CGI-S,
Clinical Global Impression – Severity ; PGI, Patient Global Impression.
a Three patients on 60–80 mg/d fluoxetine ; one patient on 300 mg/d fluvoxamine ;
one patient on 200 mg/d sertraline ; one patient on 60 mg/d citalopram.
b Two patients on 60–100 mg/d fluoxetine ; two patients on 30 mg/d S-citalopram;
one patient on 60 mg/d citalopram; one patient on 250 mg/d sertraline.
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(F=9.2, d.f.=4, p=0.001) (Fig. 1). Changes in de-
pression and anxiety were not correlated with YBOCS
and CGI-S changes from baseline. Correlations were
significant between OCD symptoms and clinical glo-
bal improvement (R=0.9, p=0.000). The sham-to-
active group after receiving 4-wk active rTMS showed
a significant improvement in general anxiety (HAMA-
14: F=3, d.f.=4, p=0.033 ; Zung-SAS: F=3.8, d.f.=4,
p=0.013), but no significant change in OCD symptoms
and depression. No change was reported in their
clinical global impression.
On average, the group that received 8-wk active
rTMS showed a 49% reduction on YBOCS (28.2¡5.8 to
14.5¡3.6), compared to a 5% reduction on YBOCS
(27.6¡5.2 to 26.3¡8.5) for those who received 4-wk
sham and 4-wk active rTMS. The group that received
8-wk active rTMS showed also a 45% reduction on
YBOCS-SR (26.5¡6 to 14.7¡2.9), while the group that
received sham and active had a 10% reduction on
YBOCS-SR (28.1¡6.9 to 25.3¡8.2). CGI-S decreased
from severe to mild in the first group and showed no
change in the other.
3-month follow-up
The eight responders (two who received 4-wk active
rTMS, four who received 8-wk active rTMS and two
who received respectively just 4-wk sham and 4-wk
sham+4-wk active rTMS) continued to meet response
criteria at 3-month naturalistic follow-up without
changes in their medications. The six responders to
active rTMS showed a 51% decrease from baseline
YBOCS (t=2.7, d.f.=8, p=0.023), a 64% YBOCS-SR
score drop (t=4.3, d.f.=8, p=0.002), and a stable
CGI-S improvement (t=3.5, d.f.=8, p=0.008) at 3
months. Significant reductions in depression and an-
xiety persisted (t=2.8, d.f.=8, p=0.023 ; t=4.5, d.f.=8,
p=0.002). Of the two responders to sham, one went on
to have 4-wk active rTMS, and they showed an aver-
age improvement of 62% on YBOCS, 48% on YBOCS-
SR, and CGI-S score of 2 at 3 months.
MT
Resting MTs are presented in Table 3. Baseline MT in
the right hemisphere was lower in patients rando-
mized to active rTMS than sham (t=x2.5, d.f.=16,
p=0.020). Both right and left hemisphere MTs at base-
line were lower in responders than non-responders
(right : t=2.1, d.f.=15, p=0.049 ; left : t=2.1, d.f.=15,
p=0.045).
Repeated-measures ANOVA revealed a significant
effect of time on the left hemisphere MT, but no timer








































































































































































































































































































































































































































































































































































































































































































































































































































































































































222 A. Mantovani et al.
interaction in right hemisphere MT. Repeated-
measures ANOVA applied separately in each group
showed that right hemisphere MT increased with time
in the active group (F=3, d.f.=4, p=0.032), and did
not change significantly in the sham group. In the
active group changes in right hemisphere MT after the
first 4-wk rTMS were correlated with clinical global
improvement (R=0.6, p=0.036).
Left/right hemispheric laterality in MT was greater
at baseline in those patients assigned to the active
rather than sham group (t=2.46, d.f.=16, p=0.031),
and this hemispheric difference was lost after 4-wk
active rTMS. Baseline laterality and change in later-
ality from baseline to 4 wk correlated with change in
CGI (R=0.7, p=0.028 and R=0.6, p=0.041, respect-
ively). Change in laterality at 4 wk correlated with
change in YBOCS-SR (R=0.7, p=0.024).
Safety
Besides one patient who fainted during MT determi-
nation, none of the others reported significant side-
effects. The TMS sessions were well tolerated. There
were no seizures, neurological complications, or sub-
jective complaints about memory or concentration
impairments. Ratings of common side-effects of TMS
showed no difference between the active and sham
groups (Table 4).
Discussion
This is the first randomized sham-controlled study
of SMA stimulation in treatment-resistant OCD. We
found that low-frequency rTMS delivered to SMA re-
sulted in more clinical responders among those
patients who completed 4-wk active treatment com-
pared to those who received sham treatment.
However, the difference in response rates was not
statistically significant probably due to the small
sample size, since a minimum of 23 subjects in each
treatment condition would have been necessary to
reach an 80% power (a=0.05). On the other hand, on
one of the continuous OCDmeasures (YBOCS-SR) and
on one continuous global measure (CGI-S), there was a
statistically significant difference between sham and
active treatment at week 4.
Response to sham was low, and in line with find-
ings that OCD patients have a low placebo response
(Huppert et al. 2004). The response rate seen with
rTMS in the present study compares favorably with
reported response rates with medications (Soomro
et al. 2008). These results support our hypothesis that
modulation of SMA via rTMS could alter symptom
expression, and encourage further work on the thera-
peutic potential of this intervention in treatment-
resistant OCD.
A few other sham-controlled studies have tested
rTMS effect in OCD (Alonso et al. 2001 ; Prasko et al.
2006 ; Sachdev et al. 2007). They targeted right or left
DLPFC and found no difference between active and
sham after 2 wk of either low- or high-frequency
rTMS. When high-frequency rTMS was applied on the
left DLPFC for up to 4 wk, there was a significant re-
duction in total YBOCS scores, but not after controlling




































Fig. 1. Clinical measures across 8 wk of active repetitive transcranial magnetic stimulation to supplementary motor area.
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our results were more favorable due to our selection of
a different cortical target. Although rTMS to DLPFC
has been shown to have an antidepressant and anxio-
lytic effect, it may be not optimal for OCD.
Our results are promising and consistent with those
found in our previous open trials, where clinical im-
provements in OCD were sustained in the follow-up
and were associated with normalization in motor
cortex excitability (Mantovani et al. 2006, 2007). Ad-
ditionally, we stimulated for up to 8 wk, while pre-
vious randomized trials stimulated for 2–4 wk. It has
previously been reported that in depression longer
rTMS treatments may be more effective (Gershon et al.
2003). Indeed, while the interpretation of the results
obtained in phase 2 is confounded by being open-
label, we found significant improvements when rTMS
was continued for four additional weeks, to a total
of 8 wk.
Improvements in depression and anxiety were also
seen. While it is possible that improvements in OCD
symptoms could be secondary to non-specific anti-
depressant or anxiolytic effects, changes in YBOCS
were not correlated with changes in depression and
anxiety, instead they were correlated with changes
in CGI. Moreover, the fact that changes in YBOCS
were independent from baseline level of depression
strengthens the hypothesis of a specific rTMS effect
on OCD with a secondary improvement in both de-
pression and general anxiety.
As we hypothesized, and consistent with our prior
reports, measures of cortical excitability correlated
with response. At baseline responders showed a lower
left and right hemisphere MT, which increased sig-
nificantly following rTMS. Furthermore, abnormal
laterality in MT at baseline (i.e. lower right MT
compared to left) predicted better response, and
laterality normalized following rTMS. Recent neuro-
physiological and neuroimaging studies suggest that
premotor and motor areas are hyperactive in OCD
(Greenberg et al. 1998, 2000 ; Yu¨cel et al. 2007).
However, it is not known whether this hyperactivity
represents part of OCD pathophysiology, or whether
it may represent a compensatory mechanism. Our
finding that baseline-increased motor-pathway excit-
ability was associated with beneficial response to in-
hibitory low-frequency rTMS is consistent with
prediction that rTMS may have been acting to nor-
malize the functional hyperexcitability associated
with OCD pathophysiology. However, confirmatory
studies will be needed to prove such a connection.
When patients initially randomized to sham received
open-label active rTMS, they did not show significant
improvement in OCD symptoms. The two groups did
not differ in demographic or clinical features, but it is
notable that they did differ in baseline brain excit-
ability measures. At baseline, a lower MT was found
in the right hemisphere of patients randomized to
active rTMS. It is possible that this difference may
have predisposed one group to be more responsive
than the other to the selected rTMS parameters. Future
studies should match groups for baseline MT to avoid
this confound and to test definitively this hypothesis.
Moreover, ongoing analyses of other neurophysiology
measures collected during the trial (such as cortical
silent period, intracortical inhibition and intracortical
facilitation) might support our hypothesis that
patients with asymmetry of excitability and particu-
larly with relatively much more excitable right hemi-
sphere might be the best candidates for inhibitory
low-frequency rTMS. While the others with a different
Table 3. Physiological measures across 4-wk active repetitive transcranial magnetic stimulation (rTMS) and sham to
supplementary motor area in 18 patients with obsessive–compulsive disorder
Dependent
measures
Active rTMS (n=9) Sham (n=9)
ANOVAa ANOVAbBaseline Week 2 Week 4 Baseline Week 2 Week 4
Right MTc 42.5¡6.4 43.7¡7.9 45¡8.7 52.6¡9.7 50.4¡11.6 48.7¡9.4 n.s. F=4.5, d.f.=4,
p=0.018




a Repeated-measures analysis of variance (ANOVA), main effect of time.
b Repeated-measures ANOVA, timergroup (active vs. sham) interaction.
c Right and Left MTs (resting motor thresholds) were measured every week; in the table we report the mean scores obtained
every 2 wk.
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neurophysiological asset might need a different rTMS
treatment set up.
However, other factors such as the psychological
effects of failing to improve after the first 4 wk of
treatment cannot be ruled out and must be considered
as a potential factor that made those patients initially
randomized to sham fail to respond to the active
treatment later.
A limitation of this study is the relatively small
sample size. A larger sample and a longer controlled
trial, given that the findings from the open-label phase
suggested that continued rTMS treatment led to ad-
ditional benefits, will be needed in the future to verify
the hypothesis of SMA-rTMS effectiveness in OCD.
Because the sham coil used looks and sounds like an
active coil but does not feel like active rTMS, patients
randomized to sham might have become unblinded
during MT determination, when they felt the tapping
sensations on the scalp, or when they received active
rTMS in phase 2. Having clinical ratings performed by
blinded clinicians, as we did in this study, would be
expected to reduce but not entirely eliminate the im-
pact of this. In future studies a sham system that feels
like active rTMS, and a best-guess questionnaire for
the patients should be used. Another limitation is the
allowance of concomitant SSRI medications. Although
we held them at stable doses for 3 months prior
to study entry and throughout, it is possible that
rTMS may have had a synergistic effect with medi-
cations, and they might confound cortical excitability
measures. Finally, half of the sample had comorbid
depression, and although we found a specific rTMS
effect on OCD that did not correlate with change in
depression, subsequent studies that exclude patients
with comorbid depression would be more definitive.
However, OCD and depression are frequently co-
morbid, making the evidence of rTMS on SMA effec-
tive in this comorbidity of special clinical relevance.
Although the study presents limitations, and the
results of this first randomized sham-controlled trial of
SMA stimulation in the treatment of resistant OCD
should be considered tentative until replication, they
are promising and support further investigation into
the potential therapeutic applications of rTMS in this
disabling condition.
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